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Article abstract-We evaluated neuropsychological test perfor1nance of 168 homosexual and bisexual n1en with and 
without human im1nunodeficiency virus (HIV) infection (113 HIV+ subjects and 55 HIV- controls) over 4,5 years of 
semiannual follow-up. Analyses of the longitudinal data were performed by applying generalized estimating equations 
(GEEs) to regres~ion analyses with repeated measures. Compared with the HIV- men, the HIV+ subjects performed 
more poorly on memory testing. Performance on all tests tended to hnprove over time, but this improven1ent was at-
tenuated or eliminated in the HIV+ group for tests of language and attention. Within the HIV+ subjects, improvement 
over time in tests of memory, executive function, language, and attention was attenuated or eliminated in patients 
with lower CD4 levels; more advanced HIV disease was associated with poorer inemory and executive function and 
with attenuated or reduced learning effects for memory, motor speed, and language tests. Clinically significant neuro-
logic findings were associated with worse memory and orientation and with attenuated or reversed learning effects for 
memory, language, and attention tests. There were 33 deaths in the HIV+ group. In the men who died, there was more 
rapid decline in executive, language, and attentional test performance. These observations remained significant after 
controlling for HIV disease severity. We conclude that HIV infecting the CNS results in progressive cognitive change 
that is closely associated with neurologic findings. In addition, our findings suggest a relation between more rapid cog-
nitive progression and death. 
We previously reported 1 a cross-sectional analysis 
that demonstrated subtle differences between per-
formance of homosexual men with and without 
human immunodeficiency virus (HIV) infection on 
a neuropsychological test hattery. Test perfor-
mance in the HIV+ subjects correlated significantly 
with an index of neurologic signs and a measure of 
cognitive complaints. We have now followed this co-
hort of homosexual and bisexual men for up to 4.5 
years and report data regarding change in perfor-
mance over time as a function of HIV status, dis-
ease severity, and neurological signs and symp-
toms. 
We have also reported that defective perfor-
mance on neuropsychological tests at the subject's 
initial visit increased the relative risk of death over 
3 years, 2 which implies that HIV in the CNS is as-
sociated with more severe disease. We report anal-
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yses here that investigate the relative rapidity of 
cognitive decline in HIV+ members of our cohort 
who did, and did not, die. 
Methods. Subjects. The recruitment and baseline char-
acteristics of this cohort have been previously described. 3 
Two hundred seven homosexual and bisexual men were 
recruited in late 1987 and early 1988 to participate in a 
5-year follow-up study of HIV-infected subjects (n = 123) 
and HIV- controls (n = 84). The majority of subjects 
were recruited by word of mouth; two announcements 
were placed in gay-oriented monthly newsletters and one 
in a newspaper. All subjects were volunteers and gave in-
formed consent. Subjects were paid for their participa-
tion in the study. One hundred sixty-eight subjects were 
entered into the longitudinal phase of the study (113 
HIV+ and 55 HIV - ) and were examined every 6 months 
for up to 10 visits. 
Assessments. At each visit, subjects received a stan-
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dardized inedical examination for the purpose of staging, 
and also received neurologic, neuropsychological, psychi-
atric, and psychosexual assessn1ents. These assess1nents 
have been described previously1,3; relevant assessn1ents 
are summarized below. 
Medical assessment. Physicians performed physical 
examinations targeted at HIV-related sympto1ns and 
signs, Subjects who met 1987 Centers for Disease Con-
trol criteria for acquired immunodeficiency syndrome 
(AIDS)4 at baseline were not included in the study, with 
two exceptions. Because of the difficulty in distinguish-
ing clinically between oral and esophageal candidiasis on 
routine physical examination, we did not exclude men 
with esophageal candidiasis, which is, on its own, a crite-
rion for AIDS. We also did not use the presence of cogni-
tive impairment as an exclusion criterion because the 
purpose of the study was to assess nervous systen1 ab-
normalities in relatively 111edically asymptomatic individ-
uals. Blood for CD4 counts was obtained at each visit. 
Following each study visit, HIV+ patients were classi-
fied by disease stages based on previously described cri-
teria. 5 For the present analyses we considered three 
severity stages: stage 1, asy1nptomatic or mildly symp-
tomatic; stage 2, signs and symptoms consistent with 
AIDS-related complex (ARC); and stage 3, AIDS. 
Neurologic assessment. All neurologic examinations 
were performed by neurologists who were blind to the 
HIV status of the subjects. In the interests of maintain-
ing blinding, the neurologic exan1inations were per-
formed prior to the elicitation of syinptoms. Each neuro-
logic sign was coded separately so that individual signs 
could be examined and factor scores could be created 
based on individual items. A standard neurologic exami-
nation was perfor1ned. Ite1ns fro1n the motor portion of 
the Unified Parkinson's Disease Rating Scale6 were in-
cluded to assess extrapyramidal function. An overall 
ineasure of neurologic disability was calculated for each 
subject, based on the Kurtzke Expanded Disability Sta-
tus Scale for n1ultiple sclerosis. 7 The Kurtzke scale re-
flects both the number of areas of neurologic dysfunction 
(ie, pyramidal tract, cerebellu1n, brainstem, etc) and the 
severity of impair1nent. Derivation of the Kurtzke scale 
for use in HIV infection has been previously described. 1 
We subdivided subjects into those with and without clini-
cally significant neurologic findings using a score of 3 or 
above on the Kurtzke scale as the cutpoint. 
Neuropsychological assess1nent. The neuropsychologi-
cal battery was also administered with the testers blind 
to HIV status. Although a larger battery was adminis-
tered at the initial visit, 1 the following tests were consis-
tently included in the battery that was administered at 
all visits: 
The 10 orientation items from the Mini-Mental State 
Examination8 were used to assess orientation to time 
and place. Attention was assessed with two types of can-
cellation tasks, one utilizing a shape and another a letter 
triad as targets,9 and with the Wechsler Adult Intelli-
gence Scale-Revised Digit Symbol subtest.10 Verbal flu-
ency was assessed with the Controlled Oral Word Associ-
ation test (60 seconds for each of the letters C, F, and 
L)11 and animal naming. 12 The Odd Man Out Test13 was 
used to assess executive or "frontal lobe" function. In this 
test of the ability to switch set, the subject is asked to 
utilize a consistent selection rule to detern1ine which of 
three symbols on a card does not belong with the other 
two. The subject must then systematically alternate be-
tween two selection rules over four trials, each consisting 
of 10 cards. The Trail Making Test was also adminis-
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tered as a test of speeded performance and, in part B, of 
rapid sequencing and set-shifting. 1'1 Motor speed and 
praxis were assessed with the Purdue Pegboard. 15 This 
test was ad1ninistered only in the first seven visits. A 12-
iteni, six-trial selective reminding test assessed verbal 
memory.16 Fifteen ininutes later, the subjects' delayed re-
call for the word list was assessed and words not recalled 
were administered in multiple-choice arrays to assess de-
layed recognition. 
To reduce the number of test scores in our analyses, 
we performed a factor analysis of the test scores at the 
baseline visit and assessed stability of the factors at the 
follow-up visits. Using these factor analyses as a guide, 
six neuropsychological factor scores were constructed. 
These included (1) memory-selective reminding test 
total score; (2) motor speed-Purdue Pegboard, pegs with 
dominant hand; (3) executive-Odd Man Out total score 
and Trails B time; (4) language-number of words re-
ported on animal naming and Controlled Oral Word As-
sociation; (5) attention-Digit Syn1bol age-scaled score, 
shape and letter cai1cellation time; and (6) orientation-
orientation score. To calculate factor scores fOr each pa-
tient) each component score was first transfor1ned into a 
z score based on the mean and standard deviation of test 
scores of all subjects assessed at the baseline visit. The z 
scores were adjusted for direction (ie, whether higher 
scores indicate better or worse performance). Factor 
scores then were calculated as sums of the z scores for 
measures within each factor. The range of scores on the 
orientation test was severely restricted (ie, few errors 
were made). For statistical purposes, perforn1ance on 
this factor was expressed as the number of errors. In this 
case only, higher scores represented poorer performance. 
Statistical analysis. Analyses of the longitudinal data 
were performed by applying generalized estimating 
equations (GEEs) to regression analyses with repeated 
measures. 17 This statistical method takes into account 
the multiple visits per subject and the fact that the char-
acteristics of a single individual over time are likely to be 
correlated with one another. The repeated measures for 
each subject (up to 10 per variable) are treated as a clus-
ter. A second advantage of GEEs is that this method 
takes into account the status or changing value of each 
covariate at each visit. Tabled values for regression anal-
yses involving the factor scores are regression coeffi-
cients and their standard error. All analyses were con-
trolled for age and education. 
The distributions of all factors except for orientation 
were approximated by a normal distribution. As noted 
above, scores for the orientation factor had an attenuated 
range and were converted to error scores; their distribu-
tion was approximated by a Poisson distribution. 
In the initial set of analyses, we examined test factor 
performance over time as a function of serostatus. The 
regression models provided estimates of the association 
of neuropsychological factor scores with serostatus, fol-
low-up time, and the interaction of serostatus and time. 
A significant interaction of HIV status and tiine would 
indicate differential rates of change in a factor score as a 
function of HIV status. 
The remaining analyses were restricted to the HIV+ 
subjects. Two sets of regression analyses explored the 
contribution of disease severity (CD4 count :::;200 
cells/mm3 versus >200 cells/mm3, or disease stage) by in-
cluding time, the disease severity measure, and the in-
teraction of time and severity in the inodel. A third set of 
analyses evaluated the relationship between neuropsy-
chological performance and clinically significant neuro-
Table 1. Baseline characteristics for HIV- and 
HIV+ subjects followed longitudinally 
HlV+ 
HlV- All men Did not die Died 
N 55 113 80 a3 
Age 38.6 (8.6) ::18.2 (8.2) 37.3 (7.9) 40.4 (8.4) 
Education 16.7 (2.a) 16.0 (2.5) 16.0 (2.4) 16.1 (2.7) 
CD4 count 823.2 (272.fi) 406.9 (220.1) 458.4 (212.0) 283.6 (192.7) 
(cells/mm3) 
CD4S20D 1.8% (1) 15.9% (18) 8.8% (7) 38.8% (11) 
Kurtzke scoro 1.1 {0.6) 1.2 (0.6) 1.3 (0.fi) 1.1 (0.8) 
Krn·tzke ~3 1.8%(1) 2.7% (3) 2.5% (2) 3.0% (l) 
Stage at bmJeline 
l 62.8% (71) 66.2fi% (53) 54.55% (18) 
2 37.2% (42) 33.75% (27) <15.45% (15) 
Values in panmtheses lire standanl ileviation8 for means and actual numbers 
for percontages. 
logic findings (Kurtzke score <3 versus ;:::3) by including 
time, neurologic impairment, and their interaction in the 
model. , 
A final set of 1'egression models was constructed to 
evaluate possible differences in test performance or pro-
gression in subjects who did and did not die during the 
study period. Similar to the analyses described above, the 
models initially explored the main effects of time, death, 
and their interaction. Subsequent analyses controlled for 
disease stage or CD4 and Kurtzke scores in order to eval-
uate the relationship between nouropsychological perfor-
mance and death independent of disease severity. 
Results. Demographics. One hundred sixty-eight 
subjects (113 HIV+ and 55 HIV-) were included in 
the longitudinal follow-up cohort. The baseline 
characteristics of these HIV+ and HIV- subjects 
are presented in table 1. Although 84 HIV - men 
were assessed at the baseline visit, the study de-
sign called for follow-up of only 55. There was no 
significant difference between the HIV- men who 
were and were not followed on any demographic or 
neuropsychological measure. 
One of the HIV- and 33 of the HIV+ subjects 
died over 5 years. Three of the HIV+ subjects died 
after completing their 10th visit. Baseline CD4 
counts of subjects who died differed significantly 
from those of HIV- subjects as well as from the 
other HIV+ subjects (table 1). Other baseline char-
acteristics did not differ between those who did and 
did not die. 
In addition to subject loss due to death, some 
subjects were lost to follow-up or refused to con-
tinue as the study progressed, and some tests could 
not be completed at some visits. The largest attri-
tion was toward the end of the follow-up period; by 
visit 9, data were available for 40 HIV- and 62 
HIV+ subjects, and by visit 10, data were available 
for 28 HIV- subjects and 51 HIV+ subjects. 
Contrasts of HIV- and HIV+ subjects. Across all 
visits, the HIV+ subjects performed more poorly 
than the HIV - subjects on the memory factor 
(table 2). In both HIV- and HIV+ subjects, perfor-
mance scores for all factors except orientation im-
proved over time. There was a significa11t serosta-
Table 2. Regression coefficients (standard error) 
assessing the association of each factor score with 
serostatus, follow-up time, and their interaction* 
Factor Serostatus Time 
Memory -0.40 (0,13)·/· 0.13 (0.03)t 
Motor speed -0.15 (0.15) 0,29 (0.05)t 
Executive -0,10 (0.24) 0.28 (0.03)1 
Language -0.24 (0.27) 0.28 (0.03)1" 
Attention 0.39 (0,38) 0.39 (0.05)t 
Orientation -0.51 (0.37) -0.04 (0.10) 
*All analyses contro1 for ago and education. 
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Figure. Mean attention factor scores for HIV- and HIV+ 
subjects at each study visit. Regression lines are derived 
from the generalized estimating equations model. 
tus X time interaction for the language and atten-
tion factors. The negative interaction indicates that 
for these factors there was less improvement in 
performance over time in the HIV+ subjects. The 
figure demonstrates this interaction for the atten-
tion factor scores. 
Analyses within HIV+ subjects. We next evalu-
ated the contribution of disease severity, measured 
by CD4 levels stratified at '.':200 cells/mm3 and >200 
cells/mm3 • For these and all subsequent analyses, 
only the regression coefficients for the interaction 
with follow-up time are tabulated. Performance on 
all factors but orientation improved over time. 
There was a significant CD4 level X time interac-
tion for the memory, executive, language, and at-
tention factors, indicating an attenuated learning 
effect or more rapid decline in performance over 
time when the CD4 count was below 200 cells/mm" 
(table 3). Since there was not a significant time ef-
fect for orientation, only the CD4 stratification was 
retained in the model, and no significant effect was 
noted. 
A similar set of models was constructed that 
measured severity by disease stage. In this model, 
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Table 3. In HIV+ subjects only, regression coefficients (standard error) for the interaction of follow-up 
time with selected clinical variables* 
Factor CD4 x Time Stage 2 X Time Stage 3 X Time Kurtzke score X Time Died X Time 
Me111ory -0.16 (0.05)t -0.13 (0.04)t -0.41 (O.lllt -0.36 (0.14)-i" 0.03 (0.07) 
Motor speed -0.10 (0.08) 0.05 (0.08) -0.37 (0.12)t -0.20 (0.14) -0.11 (0.10) 
Executive -0.19 (O.OS)t -0,01 (0.06) 0.22 (0.14) -0.18 (0.22) -0.19 (0.0S)t 
Language -0.16 (0.06Jt -0.11 (0.06) -0.30 (0.12Jt -0.43 (0.15)t -0.25 (0.07lt 
Attention -0.40 (O.l 7H -0.03 (0.11) -0.15 (0.21) -1.21 (0.49)-f" -0.62 (O. lBH 
*Variables include CD4 count (stratified at 200 cells/rnm:1), disease stage, the presence or absence of dinically signifieant neurologic findings 
(Kurtzke score stratified at 3), and whether or not the subject died. The interaction coefficients are from separate regression n1otfols assessing 
the association of each factor score with follow-up time, the clinical n1easure, and the interaction of tin1e and the clinical measure. All analyses 
control for age and education. 
t jJ < 0.05. 
performa11ce on all factors but orie11tation im-
proved significantly over tin1e, and the time vari-
able was excluded from the model assessing orien-
tation. In comparison with stage 1 (asymptomatic 
or mildly symptomatic), stage 2 (ARC) was associ-
ated with more orientation errors, and stage 3 
(AIDS) was associated with poorer performance on 
memory and executive function. There was a signif-
icant stage 2 X time interaction for memory, indi-
cating an attenuated learning effect in patients 
with ARC, and a significant stage 3 X time interac-
tion for memory, inotor speed, and language, indi-
cating an attenuated learning effect or decline in 
performance for patients with AIDS (table 3). We 
evaluated the possibility that the relationship be-
tween disease severity and motor speed might be 
due to increased numbers of men with peripheral 
neuropathy. Peripheral neuropathy was rare 
(seven me11 over all visits), and its presence was 
not related to motor speed. 
In order to investigate the relationship between 
the presence of neurologic signs and cognitive per-
formance, we constructed a model that included the 
Kurtzke scale, dichotomized at a score of 3 and 
above to represent the presence or absence of clini-
cally significant neurologic problems. Overall, all 
factors but orientation improved over time, and the 
time variable was excluded from the model assess-
ing orientation. The presence of significant neuro-
logic signs was associated with poorer performance 
on the memory factor and more orientation errors. 
There was a significant Kurtzke score X time inter-
action for the memory, language, and attention fac-
tors, indicating that the learning effect for these 
factors was attenuated or eliminated in subjects 
who had or developed clinically significant neuro-
logic signs (table 3). To evaluate the possibility that 
the relationship between neurologic signs and neu-
ropsychological factors was actually due to neuro-
logic signs being more common in advanced dis-
ease, we incorporated disease stage into the regres-
sion model. The Kurtzke score X time interactions 
remained significant. 
Factor scores in HIV+ subjects who did and did 
not die. There were 33 deaths in the HIV+ group. 
Average time between final testing and death was 
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approximately 8 months. Table 1 presents demo-
graphic data at baseline for HIV+ subjects who did 
and did not die. There was a significant death X 
time interaction for the executive, lang11age, and 
attention factors, indicating that the improvement 
in factor scores generally seen over time was atten-
uated in men who died (table 3). A subsequent 
analysis controlled for disease severity and estab-
lished that for any level of disease severity, there 
was poorer performance and more rapid progres-
sion of neuropsychological problems in men who 
died. 
Discussion. The present findings confirm and ex-
tend previous observations of cognitive change in 
HIV infection among well-educated, high-socioeco-
nomic-status homosexual and bisexual men. None 
had AIDS at the beginning of the study, and 43 
were medically asymptomatic. If neuropsychologi-
cal test performance is considered to be an indica-
tor of the effects of HIV on the CNS, the initial re-
sults would be expected to be quite subtle. Still, we 
reported1 small but statistically significant differ-
ences between the performance of HIV- and HIV+ 
subjects on some tests at baseline. These included 
performance differences on tests of memory, lan-
guage, attention, abstract reasoning, speeded pro-
cessing, and executive function. Because tests were 
administered every 6 months, subjects would be ex-
pected to have become quite familiar with the test 
materials. In fact, a striking feature of the present 
prospective analyses is the general trend for im-
proved performance over time on all the neuropsy-
chological test factors considered. The potential ef-
fects of HIV infection on performance therefore 
must be judged against a background of improving 
scores. In our comparison of the performance of the 
HIV- and HIV+ groups over time, we found that 
memory was poorer in the HN + groups at all vis-
its. In addition, for the language and attention fac-
tors, the trend toward improved performance over 
time was significantly attenuated in the HN + sub-
jects. We hypothesize that these cognitive effects 
are an early sign of a more general effect of HIV on 
the CNS. The generally poorer performance of the 
HIV+ subjects on memory tests has been noted by 
several groups in cross-sectional studies.'"8 The dif-
ferential change in language and attention also 
parallels our previous findings. 
We used factor scores to summarize neuropsy-
chological test data. While the name of each factor 
reflects our view of the primary cognitive function 
that is tapped, it is certainly the case that these 
factors reflect multiple processes. For example, the 
tests included in the attention factor also require 
psychomotor speed and scanning. 
To better understand HIV's effects on test per-
formance, subsequent analyses focused on the 
HIV+ subjects only. The significant interactions be-
tween time and disease severity (expressed either 
in terms of disease stage or CD4 counts) for many 
neuropsychological test factors indicated that the 
development of more severe disease was associated 
with more marked attenuation of the learning ef-
fect and, in most cases, with decline in performance 
over time. This observation parallels that made by 
many other investigators19-22 primarily using cross-
sectional data: the effect of HIV on neuropsycholog-
ical performance is more marked in the later stages 
of the disease. More important, the present obser-
vations confirm in prospectively collected data that 
progression in HIV disease severity is associated 
with more rapid progression of neuropsychological 
changes. 
To further test the idea that HIV can have a spe-
cific effect on the CNS, we investigated the relation 
between the emergence of neurologic abnormalities 
and neuropsychological change. We found that pa-
tients who had or developed neurologic abnormali-
ties were more likely to perform more poorly on the 
neuropsychological battery. Further, this relation-
ship remained after controlling for disease severity, 
suggesting that at any stage of severity there was 
an association between neurologic and neuropsy-
chological abnormalities. This observation is in 
agreement with our cross-sectional analyses of the 
baseline data, which suggested that HIV's effect on 
the CNS will be manifested by both cognitive and 
neurologic changes. We designed the present analy-
ses to evaluate the association of the neurologic 
and neuropsychological manifestations of HIV in-
fection at any visit, but cannot address their rela-
tive timing. The latter issue is particularly complex 
in the earlier stages of the disease because neuro-
logic signs are not always present consistently from 
one visit to the next. 
We also investigated the relationship between 
mortality and change in cognitive function over 
time. We previously reported that defective perfor-
mance on neuropsychological testing or symp-
tomatic motor complaints at the initial visit were 
associated with increased relative risk of death, 
even after controlling for disease severity indices. 
The present analyses demonstrate that the sub-
jects who died had an attenuated learning effect for 
executive tasks and relative declines in perfor-
mance on language and attention tasks. These ob-
servations remained significant after controlling 
for disease severity. These findings are unlikely to 
represent marked changes that might occur in test 
performance during severe illness immediately 
prior to death because the average time between 
the final study visit and death was approximately 8 
months. Because we studied only ambulatory sub-
jects and did not offer treatment, subjects often ter-
minated participation when they became more ill 
or had difficulty traveling to the medical center, 
and we did not have an opportunity to test severely 
ill subjects. Therefore, our findings suggest that 
when HIV affects the CNS (as indicated by neu-
ropsychological and neurologic changes), it is asso-
ciated with more rapid disease progression and 
death. 
The differences detected between HIV+ and 
HIV - men may be underestimated because HIV+ 
subjects were often not examined when they be-
came extremely ill. This may also explain, in part, 
the observed general improvement in test perfor-
mance over time: there may have been differential 
loss to follow-up of the most cognitively impaired 
individuals. Therefore, the neuropsychological 
changes observed in this study are relatively subtle 
and may underestimate actual changes to some de-
gree. An alternate possibility is that men with sys-
temic disease might not have returned for follow-
up while those with cognitive changes did. We con-
sider this unlikely, particularly since our analyses 
indicate a relationship between disease severity 
and cognitive change. In any case, the present find-
ings confirm our initial cross-sectional observations 
that HIV in the CNS results in progressive cogni-
tive changes that are closely associated with neuro-
logic findings. 
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